(19)
(11) EP 3 846 783 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.11.2023 Bulletin 2023/47

(45) Mention of the grant of the patent:
18.10.2023 Bulletin 2023/42

(21) Application number: 19816295.0

(22) Date of filing: 04.12.2019
(51) International Patent Classification (IPC): 
A61K 9/14(2006.01)
A61K 9/70(2006.01)
A61P 37/06(2006.01)
 A61K 9/51(2006.01)
A61K 31/436(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/145; A61K 9/146; A61K 9/5123; A61K 9/513; A61P 37/06; A61K 9/006; A61K 9/7007; A61K 9/5192; A61K 9/7046; A61K 31/436
(86) International application number:
PCT/EP2019/083691
(87) International publication number:
WO 2020/115140 (11.06.2020 Gazette 2020/24)

(54)

NANOPARTICLES COMPRISING TACROLIMUS

NANOPARTIKEL MIT TACROLIMUS

NANOPARTICULES COMPRENANT DU TACROLIMUS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 04.12.2018 DE 102018130848

(43) Date of publication of application:
14.07.2021 Bulletin 2021/28

(73) Proprietor: Nucleus Medical GmbH
82031 Grünwald (DE)

(72) Inventors:
  • BEIER, Wolfgang
    81545 Munich (DE)
  • HORSTKOTTE, Elke
    81245 Munich (DE)

(74) Representative: Engelhard, Markus 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A1-2006/066063
   
  • AHMED S. ZIDAN: "Taste-masked tacrolimus-phospholipid nanodispersions: dissolution enhancement, taste masking and reduced gastric complications", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 22, no. 2, 17 February 2017 (2017-02-17), pages 173-183, XP055667592, US ISSN: 1083-7450, DOI: 10.3109/10837450.2016.1138131
  • Ruihua Wang: "FK506-loaded solid lipid nanoparticles: Preparation, characterization and in vitro transdermal drug delivery", African Journal of Pharmacy and Pharmacology, vol. 6, no. 12, 29 March 2012 (2012-03-29) , XP055748514, DOI: 10.5897/AJPP11.831
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).